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Nephrotic syndrome (NS) is a glomerular disease that is defined by the leakage of protein into the urine and is associated
with hypoalbuminemia, hyperlipidemia, and edema. Steroid-resistant NS (SRNS) patients do not respond to treatment with
corticosteroids and show decreased Wilms tumor 1 (WT1) expression in podocytes. Downregulation of WT1 has been shown to
be affected by certain microRNAs (miRNAs). Twenty-one patients with idiopathic NS (68.75% were SSNS and 31.25% SRNS) and
10 healthy controls were enrolled in the study. Podocyte number and WT1 location were determined by immunofluorescence, and
the serum levels of miR-15a, miR-16-1, and miR-193a were quantified by RT-qPCR. Low expression and delocalization of WT1
protein from the nucleus to the cytoplasm were found in kidney biopsies of patients with SRNS and both nuclear and cytoplasmic
localization were found in steroid-sensitive NS (SSNS) patients. In sera from NS patients, low expression levels of miR-15a and
miR-16-1 were found compared with healthy controls, but only the miR-16-1 expression levels showed statistically significant
decrease (𝑝 = 0.019). The miR-193a expression levels only slightly increased in NS patients. We concluded that low expression
and delocalization from theWT1 protein in NS patients contribute to loss of podocytes while modulation fromWT1 protein is not
associated with the miRNAs analyzed in sera from the patients.
1. Introduction
Nephrotic syndrome (NS) is one of the most common
diseases in children and is characterized by the leakage of
large amounts of protein into the urine, lipidemia, hypoalbu-
minemia, and dysfunction of the glomerular filtration barrier
[1]; NS is also amajor cause of podocyte injury [2]. Podocytes,
highly specialized cells of the visceral epithelium, are found in
the glomerular membrane of the kidney [3]; they constitute
the terminal part of the ultrafiltration barrier that prevents
protein loss, which can result in damage and detachment of
podocytes. The reduction of glomerular podocytes in lupus
nephritis (LN) patients is correlated with the cumulative loss
of urinary podocytes and proteinuria during the progression
of kidney disease [2, 4].
Some urinary biomarkers have been found to be associa-
ted with injured podocytes in urine sediment, such as podo-
calyxin (PODXL), nephrin (NPHS1), podocin, and Wilms
tumor protein (WT1) [5]. WT1 itself has been found in exo-
somes in urine sediment, indicating podocyte injury [6].
WT1 is essential for urogenital development, and its exp-
ression is limited to mature podocytes [7]. TheWT1 gene en-
codes for a transcription factor that is critical for the develop-
ment of podocytes and viability; the regulation of podocyte
homeostasis occurs via PODXL and NPHS1 [7].
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Recent studies have demonstrated that mutations inWT1
can lead to syndromic forms of steroid-resistant NS (SRNS),
such as Denys-Drash or Frasier syndrome, and can cause
isolated SRNS [8, 9]. Between 10% and 20% of patients
fail to respond to steroid therapy; thus, the prognosis for
SRNS is usually poor, due to the increased risk of developing
end-stage renal disease [10, 11]. Beltcheva et al. reported
a case of a pediatric patient with SRNS that was caused
by a novel dominant WT1 mutation, C11184A, identified in
exon 9 [10]. Mutations within WT1 are frequent causes of
sporadic, isolated cases of SRNS in girls [8].WT1 expression
is modulated by microRNAs (miRNAs) [12], which are small
(20–25 nucleotides), noncoding RNA molecules that act as
posttranscriptional regulators of gene expression in animals
and plants, participating in many key biological processes
[13]. In the kidney, miRNAs play critical roles in renal devel-
opment, homeostasis, and physiological function. Several
studies have shown thatmiRNAs are also keymediators of the
pathogenesis of various renal diseases [14–16]. Furthermore,
miRNAs can be secreted into the extracellular environment
and detected in fluids, including urine and serum.They have
been proposed as biomarkers for a wide range of diseases
[17, 18].
Gao et al. discovered that miRNAs 15a and 16-1 may func-
tion as tumor suppressors to regulate leukemic cell prolif-
eration, potentially by downregulating the WT1 oncogene
[12]; pure curcumin was also recently shown to modulate the
expression of WT1, partly by upregulating the expression of
miR-15a and miR-16-1 in leukemic cells [19].
In the podocytes of patients with focal segmental
glomerulosclerosis (FSGS), the expression of miR-193a was
induced, which in turn inhibited the expression of WT1,
modulating the expression of genes critical for podocyte
architecture [20].The presence of miRNAs in plasma, serum,
and urine was also shown to be a possible biomarker of dia-
betic kidney disease [21]. Another mechanism of modulation
ofWT1 that has been observed in experimental mice during
the sepsis is the decrease of nuclear WT1 in podocytes and
was associated with transcriptional suppression of nephrin
and cause albuminuria [22].
The aim of this study was to determine whether there are
different expression levels and protein localization of WT1
in SRNS and SSNS patients and its relationship with the
miR-15a, miR-16-1, and miR-193a, which modulate the WT1
expression in other models.
2. Methods
Twenty-one biopsies, serum and urine samples from 11 males
and 10 females, from patients diagnosed withNSwhomet the
criteria of International Study of Kidney Disease in Children
with proteinuria levels greater than 3.5 g/24 h were included,
in the control group serum and urine samples were obtained
from 10 subjects without kidney disease, renal biopsies were
obtained of autopsy subjects without renal disease who died
in accidents as a result of a head injury. Patients who agreed
to participate in the study signed a letter of informed consent.
This study was performed with patients living in the north-
central region from Mexico, according to the principles of
the Declaration of Helsinki, and was approved by the ethics
committees of our institutions.
2.1. Sample Processing. Freshly urine samples were processed
in less than 30min, and 10mL of urine was centrifuged for
5min at 1,500 rpm.After decanting the supernatant, the pellet
was resuspended in 1mL PBS-TS (0.1% Tween-20 and 0.02%
SDS in phosphate-buffered saline [PBS]); 25 𝜇L of which was
fixed at 55∘C for 10min for continued permeabilization as
described below.
2.2. Immunofluorescence. As the localization ofWT1 is essen-
tial for its biological action, WT1 localization was assessed
for all samples. For the analysis of the number of podocytes
per glomerulus in both NS patients and healthy subjects,
WT1 and nephrin were used as biomarkers for immunoflu-
orescence of 4 𝜇m thick sections of renal tissue mounted
on microscope slides. The specimens were dewaxed, per-
meabilized with Triton X-100 (Triton 0.1% with 1% sodium
citrate in PBS), and washed three times with PBS.The tissues
were blocked with 20% fetal bovine serum (FBS) in PBS
for 30min and incubated for 1 h with monoclonal anti-
WT1 antibody (WT1 [F-6] sc-7585, monoclonal mouse IgG1,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-
nephrin monoclonal antibody (H-300 sc-28192, polyclonal
rabbit IgG, Santa Cruz Biotechnology) diluted 1 : 100 in 10%
FBS in PBS. After washes with PBS, the presence of bound
antibody was identified by goat anti-mouse IgG1 Texas Red
(sc-2979, Santa Cruz Biotechnology) and goat anti-rabbit
IgG-FITC (sc-2012, Santa Cruz Biotechnology) staining.
Some slides were counterstained with 4󸀠,6-diamidino-2-
phenylindole (DAPI). Finally, the slides were mounted and
examined by confocal scanning microscopy. The intensity of
the signal was expressed in pixels and analyzed using Image-
Pro Plus software, version 7.0 (Media Cybernetics, Rockville,
MD, USA).TheWT1 localization was determined by Pearson
correlation coefficient (PCC) [23].
2.3. Blood Collection. Five mL whole blood samples from NS
patients and healthy controls were collected in tubes (BD
Vacutainer; Becton Dickinson Vacutainer Systems, Franklin
Lakes, New Jersey, USA) and then processed for obtain the
serum by centrifugation at 1,500 rpm for 10min. The sera
were stored at −70∘C until analysis.
2.4. RNA Isolation and Quantification. Total RNA was extra-
cted from patient sera using the miRNeasy Serum/Plasma
Kit (QIAGEN, Hilden, Germany), according to the manufac-
turer’s instructions. Two aliquots of 200 𝜇L each were used to
obtain sufficient RNA to perform all quality tests. RNA was
dissolved in diethylpyrocarbonate-treated water, and RNA
quality and quantity were determined by spectrophotometry
using the NanoDrop ND-1000 (NanoDrop Technologies,
Wilmington, DE, USA).
2.5. cDNA Synthesis and Real Time RT-PCR (qPCR) Assay for
miRNAsExpression. TodeterminewhethermiR-15a,miR-16-
1, and miR-193a are involved in regulating the expression of
WT1, their expressionwas quantified in sera fromNS patients
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Table 1: Description of NS patients and controls.
Age Gender % Treatment % Proteinuria
Nephrotic syndrome 5.58 (range 2–12 years) Males 52 SSNS 68.75 4.01 g/24 h
Females 48 SRNS 31.25
Healthy subjects 9 (range 3–12 years) Males 30.77 No treatment <0.3 g/L
Females 69.23
SSNS: steroid-sensitive nephrotic syndrome; SRNS: steroid-resistant nephrotic syndrome.
and healthy controls. Total RNA was polyadenylated and
subjected to reverse transcription using an NCode miRNA
First-Strand cDNA Synthesis Kit (Invitrogen Carlsbad, CA)
according to the manufacturer’s instructions.
Real-time qPCR analysis was carried out using SYBR
Green PCR Master Mix (Applied Biosystems; Foster City,
CA, USA) on an ABI 7500 Fast Real-Time PCR System
(Applied Biosystems). The primers reported by Gao et al.
[12] were used to quantify the relative expression levels of
miR-15a,miR-16-1, andmiR-193a in the samples. Experiments
were performed in triplicate. U6 was used as an endogenous
control. The expression of each miRNA relative to U6 RNA
was calculated using the equation 2−ΔΔCT [24–26].
2.6. RNA Isolation and qPCR for WT1 mRNA Expression.
Total RNA was isolated from renal biopsies using the
High Pure RNA Isolation Kit and High Pure RNA Paraffin
Kit (Roche Life Science, Mexico) according to the manu-
facturer’s instructions. Single-stranded cDNA was synthe-
sized by reverse transcription using the miScript Reverse
Transcription Kit (Qiagen, United States) according to the
manufacturer’s instructions. Real-time PCR was performed
using the ABI 7500 Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA) with TaqMan gene
expression assays. Comparative real-time PCR assays were
performed for each sample in triplicate.Theprimers forWT1-
F: 5󸀠-TCTGCGGAGCCCAATACAG-3󸀠; WT1-R: 5󸀠-CAC-
ATCCTGAATGCCTCTGAAGA-3󸀠; and WT1-P FAM: 5󸀠-
CACCGTGCGTGTGTATT-TAMRA-3󸀠 were used.The com-
parative quantification cycle threshold (Cq) method was used
to determine the relative expression levels of the WT1 gene.
The 18S rRNA (Applied Biosystems, Foster City, CA, USA)
gene was used for normalization.
2.7. Statistical Analyses. Statistical analyses were performed
using SPSS 17.0 software.The results are presented as themean
± SD. Comparisons were made using an analysis of variance
and Student’s 𝑡-test, and the association between miRNA
levels and expression of WT1 was assessed by Pearson’s
correlation statistical program and considered significant at
p value less than or equal to 0.05.
3. Results
3.1. Sample Description. Twenty-one samples from patients
with NS and 10 healthy subjects without renal disease as con-
trol group (Table 1) were analyzed for levels of creatinine (0.39
± 0.25mg/dL), proteinuria (4.01 ± 2.7 g/24 h), cholesterol
(207.06 ± 91.72mg/dL), triglycerides (141.56 ± 93.55mg/dL),
and albumin (3.75 ± 0.83 g/dL). Control renal biopsies were
obtained from autopsy subjects without renal disease who
died in accidents as a result of a head injury.
3.2. WT1 Localization in Podocytes in NS Patients and Healthy
Subjects. Immunofluorescence of renal biopsy tissue using
WT1 as a biomarker showed a decrease of 27% in NS patients
compared to healthy subjects (Figure 1(a)). The localiza-
tion of WT1 in SRNS patients was primarily cytoplasmic,
whereas WT1 in SSNS patients showed both a nuclear and
a cytoplasmic localization while in healthy controls it was
mainly nuclear. The localization assay was performed by the
colocalization of DAPI (nuclear localization) and Texas Red
(WT1), showing a statistically significant difference between
SSNS (PPC = 0.51 ± 0.03) and SRNS (PPC = 0.29 ± 0.01)
patients compared with healthy subjects (PPC = 0.73 ±
0.02) (p = 0.00001) (Figure 1(c)). In urine sediments of
SRNS patients, detached podocytes showed a cytoplasmic
localization of WT1 (PPC = 0.35 ± 0.08) (Figure 1(b)). These
results were significantly different from those in healthy
subjects (PPC = 0.64 ± 0.03) (p ≤ 0.0001; Figure 1(d)).
3.3. Analysis of WT1 Expression in Podocytes of NS Patients
and Healthy Controls. WT1 expression analysis in podocytes
was performed by two methods: immunofluorescence and
RT-qPCR. WT1 expression by intensity pixels in renal biop-
sies of patients with NS was statistically different than healthy
controls (p = 0.0001) and between patients with SSNS and
SRNS (p = 0.05; Figure 2(a)), with highest levels in healthy
controls and lowest levels in SRNS patients. WT1 RNA
expression levels were analyzed by RT-qPCR in renal biopsies
of NS patients and healthy controls, showing significantly
lower (66%) WT1 mRNA levels in NS patients (p = 0.017),
indicating a decrease in basalWT1 levels in the podocytes of
NS patients (Figure 2(b)).
3.4. Expression of miR-15a, miR-16-1, and miR-193a Levels
in Sera from NS Patients. The expression levels of miR-15a
(2−ΔΔCT) did not differ between the different groups (SRNS
0.33 ± 0.12, SSNS 0.91 ± 0.44, and HS 1.54 ± 0.54 of relative
expression) (p = 0.138; Figure 3(a)) or between patients
with SRNS and SSNS compared to the control group (p
= 0.31; Figure 3(b)). While the expression of miR-16-1 was
significantly lower (0.54 ± 0.144 relative expression) in the
sera of NS patients compared with healthy controls (1.86 ±
0.82 relative expression) (p = 0.019; Figure 3(c)), there was
no difference between SSNS and SRNS patients (p = 0.14;
Figure 3(d)). The relative expression of miR-193 (2−ΔΔCT)
did not differ between NS patients (2.14 ± 0.36 relative






















































Figure 1: WT1 expression and localization in podocytes from biopsies and urinary sediments of patients with NS. (a) Immunofluorescence
of renal biopsies (magnification, ×40) of patients with nephrotic syndrome (NS). (b) Immunofluorescence of podocytes in urine sediments:
nephrin detection was used as a second marker of podocytes (magnification, ×40). (c) Colocalization of DAPI and Wilms tumor 1 (WT1)
in nucleus/cytoplasm of podocytes in kidney biopsies. (d) Colocalization of DAPI and WT1 in nucleus/cytoplasm of podocytes in urinary
sediments. The colocalization was determined by Pearson correlation coefficient (PCC). ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001.
expression) and controls (2.30 ± 0.75 relative expression, p =
0.59; Figure 3(e)) or between patients with SRNS and SSNS
(p = 0.91; Figure 3(f)).
3.5. Relationship betweenWT1 and miRNAs. We did not find
a significant correlation between WT1 expression and serum
concentrations of miR-15a, miR-16-1, and miR-193a in NS
patients (miR-15a: 𝑟 = 0.118, p = 0.882; miR-16-1: 𝑟 = 0.301,
p = 0.969; and miR-193a: 𝑟 = 0.213, p = 0.787). However, a
positive correlation was found between miR-15a and miR-16-
1 (𝑟 = 0.994, p = 0.006). There was no significant relationship
between the particular miRNA levels.
4. Discussion
Epidemiological studies indicate that NS remains the most
common manifestation of glomerular disease in childhood,
often causing death from untreated infections [27]. The
present study reviewed 21 children with NS in the Mexican
mestizo population, with an average age of 5.8 years.
Idiopathic NS is one of the most common glomerular
diseases in pediatrics. The response to steroids is the best
prognostic factor in this disease, and most children with NS
respond to corticosteroids. However, 70% of children experi-
ence recurrence, with episodes of edema andproteinuria [28];
fewer than 3% of patients with SSNS progress to chronic renal
failure compared to 50% patients with SRNS [29].
The WT1 protein has been used as a biomarker of podo-
cyte loss from glomeruli in kidney disease [30, 31] and of the
presence of damaged podocytes in urinary sediment [32, 33].
In this work, we clearly observed a reduction of podocytes
in renal biopsies of children with NS and the presence of
podocytes in the urine, but the reason for such podocyte








































Figure 2: WT1 expression in podocytes from renal biopsies of patients with NS. (a) WT1 expression immunofluorescence. HS: healthy
subjects; SSNS: steroid-sensitive NS; and SRNS: steroid-resistant NS.WT1 expression was measured by pixel intensity. (b) Relative expression
levels of WT1 by real-time PCR. ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001.
detachment is not clear. The cause may be an imbalance
between different isoforms of WT1 or decreased basal pro-
tein expression. Different research groups have observed a
decrease in WT1 protein expression in children with SRNS,
which was often accompanied by WT1 mutations in exons
8 and 9 [8, 34, 35]. However, another report suggested that
reduced expression levels of WT1 cause glomerulonephritis
andmesangial sclerosis, depending on the level of the protein
[36].
We found normal WT1 expression in the nuclei of
podocytes from biopsies of healthy controls without kidney
disease; however, in SSNS patients, WT1 expression was
localized to both the nucleus and cytoplasm, whereas WT1
expression is primarily cytoplasmic in SRNS patients, sug-
gesting that delocalization of WT1 from the nucleus can lead
to a loss of function as a transcription factor. Decreased
expression levels of WT1 lead to downregulation of its target
genes PODXL (podocalyxin) andNPHS1 (nephrin), as well as
several other genes crucial for the architecture of podocytes,
initiating a catastrophic collapse of the entire podocyte-
stabilizing system [20]. Additionally, Kato et al. [22] observed
that in Lipopolysaccharide (LPS) treated mice, a loss of
albumindecreasednephrin levels and the nuclear localization
ofWT1 in podocytes.The nuclear localization ofWT1, as well
as nephrin mRNA and protein levels, returned to near basal
levels 72 hours after LPS with recovery of albumin levels [22].
The loss of WT1 gene expression could be a fatal con-
sequence as described above [9]; the regulation of WT1
is provided by certain genes, such as PAX2 and PAX8, or
epigenetic modulation mechanisms, such as miRNAs [12,
19]. In addition, WT1 has the ability to self-regulate [37].
In this study, we assessed whether low WT1 expression
in podocytes correlates with the circulating levels of miR-
15a, miR-16-1, and miR-193a in the sera of NS patients.
Our results indicate that the expression of miR-15a was
higher in healthy controls than in NS patients but was not
statistically significant. Similar results were observed formiR-
16-1, but the difference between the expression of miR-16-
1 in NS patients and in healthy controls was significant,
indicating an inverse relationship betweenmiRNAs andWT1
expression. Gao et al. reported that miR-15a and miR-16-
1 inhibit the proliferation of leukemic cells by decreasing
WT1 levels via joining WT1-3󸀠UTR. The expression of these
miRNAs inhibits cell proliferation, promotes apoptosis of
cancer cells, and suppresses tumorigenicity both in vitro and
in vivo [12]. Both miR-15a and miR-16-1 have been shown to
negatively affect several oncogenes, including BCL2, MCL1,
CCND1, andWNT3A. Downregulation of these miRNAs has
been reported in chronic lymphocytic lymphoma, pituitary
adenoma, and prostatic carcinoma [37, 38], while miR-
193a was not found to elicit any significant effects on these
cancers. However, the data reported by Gebeshuber et al. [20]
indicated that miR-193a is involved in FSGS by decreasing
WT1 levels. In conclusion, we found low WT1 expression
and delocalization in NS patients. We also observed higher
expression levels of miR-15a and miR-16-1 in healthy controls
compared with NS patients, but only miR-16-1 levels were
statistically different. However, we did not find a correlation
between miRNA expression and WT1 levels. It is important
to extend the search for miRNAs as biomarkers of renal
diseases as well as to understand the basic mechanisms of
gene regulation of podocytes and the glomerular filtration
system.
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Figure 3: Expression of miR-15a, miR-16-1, and miR-193a in sera from patients with NS. Relative expression levels of miR-15a (a) in patients
withNS (nephrotic syndrome) and healthy subjects (HS) and (b) in patients with steroid-sensitiveNS (SSNS) and steroid-resistantNS (SRNS).
miR-16-1 (c) in patients with NS and HS and (d) in patients with SSNS and SRNS and miR-193a (e) in patients with NS and HS and (f) in
patients with SSNS and SRNS.∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001.
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